Tesla Supercharger Surge: GM And Ford EVs Begin To Roll In
What a difference a reliable charging network makes.
Earlier this month when I arrived at a massive Tesla Supercharger location (76 chargers) at Tejon Outlets in Southern California just off Interstate 5, the only other cars charging were a Honda Prologue EV and Ford Mustang Mach-E. So, for a moment, there wasn't a single Tesla. Only the Prologue, Mach-E, and a GMC Sierra Denali EV (which I was driving) and a vast, empty sea of available charging spots. Teslas began showing up soon thereafter but it was odd to see only non-Tesla EVs using the chargers. And refreshing to see so many available stalls.
And it gets even better. Less than a mile away, across Interstate 5, there was another Tesla Supercharger location with 24 chargers. And in nearby Lebec – about 20 minutes from the outlets on Interstate 5 – there was a spanking-new Supercharger location with 38 new super-fast v4 Superchargers. Not to mention the multiple Supercharger locations in Santa Clarita, Calif (further south on Interstate 5) and the three locations near my home in northwest Los Angeles.
Charging a Cadillac Escalade IQ at a Tesla Supercharger in Simi Valley, Calif.
A massive Tesla Supercharger location at Tejon Outlets near Bakersfield, Calif. Available Tesla ... More Superchargers as far as the eye can see.
Competition isn't even close
A night-and-day difference from competing networks such as Electrify America, which I've used extensively over the years. By comparison, there is no nearby Electrify America charging location in the long stretch of Interstate 5 between Santa Clarita, Calif and Bakersfield, Calif. versus the 130+ Tesla Superchargers in that same stretch of highway.
And even if you find one, the charging experience is very different: a handful of chargers (often no more than 8), lines, and long waits. Not to mention the hit-or-miss vagaries of Electrify America chargers: one day everything works, the next day multiple chargers are down.
Waiting, waiting, waiting…
I've been waiting for Electrify America to locate a charger near my home. But that's never happened. Despite the very high density of EVs in the northwest Los Angeles area where I live, there are no Electrify America charging stations. Not one. The closest location is in Van Nuys, Calif with 3 fast chargers (level 3) and one slow level 2 charger. So, that's a total of 3 Electrify America fast chargers in a vast area in northwest Los Angeles covering high-density EV hotspots such as Chatsworth, Porter Ranch, Granada Hills, and Simi Valley (Ventura County). Yes, there are three Electrify America locations in Santa Clarita, Calif but that's further north bordering the high desert.
GM, Ford, others need Tesla
Not everyone charges at home. At least 50 percent (and often more) of the Tesla superchargers near my home are usually being used. And lack of public charging is often cited by prospective EV buyers as a reason they hesitate to purchase an EV. GM and Ford are now offering NACS (Tesla) adapters for their EVs (see my video below) but they will soon offer NACS ports built in. That can't happen soon enough.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress
DENALI Phase 2 trial evaluating azenosertib in patients with Cyclin E1-positive PROC remains on track with topline data anticipated by year end 2026, with the potential to support an accelerated approval, subject to FDA feedback $303.4 million cash, cash equivalents and marketable securities supports operational runway into late 2027 SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, announced financial results for the second quarter 2025 and highlighted recent operational progress. 'This quarter, we continued to execute on our focused strategy to advance the late-stage clinical development of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). There is no approved treatment option specifically for this biomarker selected population, which comprises approximately 50% of PROC patients,' said Julie Eastland, Chief Executive Officer of Zentalis. 'We are maintaining momentum with the DENALI Phase 2 clinical trial and remain on track to disclose topline data from DENALI Part 2 by year end 2026.' Business Updates Phase 2 DENALI clinical trial remains on track. Enrollment is ongoing in DENALI Part 2a of the Phase 2 DENALI clinical trial (NCT05128825) of azenosertib in patients with Cyclin E1-positive PROC. DENALI Part 2a is designed to confirm the primary dose-of-interest with a target enrollment of up to approximately 30 patients at each of two dose levels: 400mg QD 5:2 (intermittent daily dosing with a five days on, two days off dosing schedule) and 300mg QD 5:2. DENALI Part 2b is designed to enroll approximately 70 patients at a single dose, the selection of which will be informed by the Part 2a results, subject to FDA feedback. The Company expects to disclose topline data from DENALI Part 2 (Part 2a and Part 2b) by year end 2026. DENALI Part 2, if successful, has the potential to support an accelerated approval, subject to FDA review. Completed strategic restructuring announced in January 2025, supporting late-stage clinical development of azenosertib. The Company has operationally completed the restructuring and does not expect to incur further associated related non-recurring expenses. This restructuring prioritizes the late-stage development of azenosertib and extends the Company's cash runway into late 2027, beyond the Company's anticipated DENALI Part 2 topline data. Second Quarter 2025 Financial Results Cash, Cash Equivalents and Marketable Securities Position: As of June 30, 2025, the Company had cash, cash equivalents and marketable securities of $303.4 million, which includes $16.8 million representing the June 30, 2025 fair value of Immunome common stock received by the Company from the sale of its ROR1 antibody-drug conjugate (ADC) product candidate and ADC platform to Immunome in October 2024. The Company believes that its existing cash, cash equivalents and marketable securities as of June 30, 2025 will be sufficient to fund its operating expenses requirements into late 2027. Research and Development Expenses: Research and development (R&D) expenses for the three months ended June 30, 2025 were $27.6 million, compared to $48.4 million for the three months ended June 30, 2024. The decrease of $20.8 million was primarily due to decreases of $15.9 million for clinical expenses, $3.6 million for lab services, $3.4 million for drug manufacturing, $0.6 million related to personnel expenses and $0.4 million of miscellaneous expenses. These decreases were partially offset by an increase in companion diagnostic expense of $3.1 million. General and Administrative Expenses: General and administrative expenses for the three months ended June 30, 2025 were $8.4 million, compared to $16.7 million during the three months ended June 30, 2024. This decrease of $8.3 million was attributable to a decrease of $6.8 million in personnel expense, $1.1 million related to consulting and $0.4 million miscellaneous expenses. Operating Expenses: Total operating expenses were $36.1 million for the three months ended June 30, 2025, compared to $65.1 million for the three months ended June 30, 2024. About AzenosertibAzenosertib is a novel, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated as a monotherapy and combination clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death. About DENALI Clinical Trial DENALI is a multi-part Phase 2 clinical trial studying azenosertib in platinum-resistant ovarian cancer (PROC) patients. Part 1b enrolled patients with PROC regardless of Cyclin E1 protein expression, all treated at 400mg 5:2 (intermittent daily dosing with a five days on, two days off dosing schedule). Interim results from Part 1b were presented at the Society of Gynecologic Oncology (SGO) 2025 Annual Meeting. Part 2 is ongoing and is enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis' proprietary immunohistochemistry cutoff. Part 2 includes Part 2a, a dose confirmation portion evaluating two doses, 300mg 5:2 and 400mg 5:2, and Part 2b, a portion designed to complete enrollment at the selected dose. Part 2, in total, is designed for accelerated approval, pending study outcome and discussions with the U.S. Food and Drug Administration. About Zentalis PharmaceuticalsZentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego. For more information, please visit Follow Zentalis on LinkedIn at Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the potential of azenosertib; our anticipated milestones and the timing thereof, including the anticipated timing of clinical data disclosures; the potential to advance research on additional areas of opportunity for azenosertib outside PROC; our anticipated cash runway; the potential for azenosertib to be first-in-class and best-in-class; the broad franchise potential of azenosertib; the planned design of our clinical trials, including DENALI Part 2; maintaining momentum and remaining on track relating to the execution of DENALI; our planned clinical development strategy and regulatory strategy for azenosertib and the timing thereof, including the potential for DENALI Part 2 to support an accelerated approval; and our expectation to not incur further non-recurring expenses associated with the restructuring. The terms 'advance,' 'anticipated,' 'believe,' 'continue,' 'design,' 'expect,' 'opportunity,' 'potential,' 'runway,' 'target,' and 'will' and similar references are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability; we have and expect to continue to incur significant losses; our need for additional funding, which may not be available; our substantial dependence on the success of azenosertib; our plans, including the costs thereof, of development of companion diagnostics; the outcome of preclinical testing and early trials may not be predictive of the success of later clinical trials; failure to identify additional product candidates and develop or commercialize marketable products; potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process or ongoing regulatory obligations; failure to obtain U.S. or international marketing approval; our product candidates may cause serious adverse side effects; inability to maintain our collaborations, or the failure of these collaborations; our reliance on third parties; effects of significant competition; the possibility of system failures or security breaches; risks relating to intellectual property; our ability to attract, retain and motivate qualified personnel, and risks relating to management transitions; significant costs as a result of operating as a public company; and the other important factors discussed under the caption 'Risk Factors' in our most recently filed periodic report on Form 10-K or 10-Q and subsequent filings with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release. Zentalis Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations (Unaudited) (In thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 License Revenue $ — $ — $ — $ 40,560 Operating Expenses Research and development 27,610 48,386 54,857 97,971 General and administrative 8,448 16,762 19,028 32,502 Restructuring — — 7,796 — Total operating expenses 36,058 65,148 81,681 130,473 Loss from Operations (36,058 ) (65,148 ) (81,681 ) (89,913 ) Other Income (Expense) Investment and other income (expense), net 9,184 (22,863 ) 6,528 12,085 Net loss before income taxes (26,874 ) (88,011 ) (75,153 ) (77,828 ) Income tax expense — 266 — 409 Net loss (26,874 ) (88,277 ) (75,153 ) (78,237 ) Net loss attributable to noncontrolling interests — — — (28 ) Net loss attributable to Zentalis $ (26,874 ) $ (88,277 ) $ (75,153 ) $ (78,209 ) Net loss per share outstanding, basic and diluted $ (0.37 ) $ (1.24 ) $ (1.05 ) $ (1.10 ) Common shares used in computing net loss per share, basic and diluted 71,992 71,040 71,836 70,969 Zentalis Pharmaceuticals, Inc. Selected Condensed Consolidated Balance Sheets Data (Unaudited) (In thousands) As of June 30, As of December 31, 2025 2024 Cash, cash equivalents and marketable securities $ 303,431 $ 371,084 Working capital(1) 272,574 333,341 Total assets 351,707 430,337 Total liabilities 77,212 93,151 Total Zentalis equity $ 274,495 $ 337,186 (1)The Company defines working capital as current assets less current liabilities. Contact: Aron FeingoldVP, Investor Relations & Corporate Communicationsir@
Yahoo
42 minutes ago
- Yahoo
AppLovin (NASDAQ:APP) Misses Q2 Sales Targets
Mobile app advertising platform AppLovin (NASDAQ: APP) missed Wall Street's revenue expectations in Q2 CY2025, but sales rose 16.5% year on year to $1.26 billion. On the other hand, next quarter's outlook exceeded expectations with revenue guided to $1.33 billion at the midpoint, or 1.3% above analysts' estimates. Its GAAP profit of $2.39 per share was 20.4% above analysts' consensus estimates. Is now the time to buy AppLovin? Find out in our full research report. AppLovin (APP) Q2 CY2025 Highlights: Revenue: $1.26 billion vs analyst estimates of $1.27 billion (16.5% year-on-year growth, 1.2% miss) EPS (GAAP): $2.39 vs analyst estimates of $1.98 (20.4% beat) Adjusted EBITDA: $1.02 million vs analyst estimates of $992 million (0.1% margin, 99.9% miss) Revenue Guidance for Q3 CY2025 is $1.33 billion at the midpoint, above analyst estimates of $1.31 billion EBITDA guidance for Q3 CY2025 is $1.08 billion at the midpoint, above analyst estimates of $1.06 billion Operating Margin: 76.1%, up from 36.2% in the same quarter last year Free Cash Flow Margin: 61%, up from 56% in the previous quarter Market Capitalization: $127.9 billion Company Overview Co-founded by Adam Foroughi, who was frustrated with not being able to find a good solution to market his own dating app, AppLovin (NASDAQ:APP) is both a mobile game studio and provider of marketing and monetization tools for mobile app developers. Revenue Growth Reviewing a company's long-term sales performance reveals insights into its quality. Any business can put up a good quarter or two, but the best consistently grow over the long haul. Over the last three years, AppLovin grew its sales at a decent 22.1% compounded annual growth rate. Its growth was slightly above the average software company and shows its offerings resonate with customers. This quarter, AppLovin's revenue grew by 16.5% year on year to $1.26 billion but fell short of Wall Street's estimates. Company management is currently guiding for a 11% year-on-year increase in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 13.3% over the next 12 months, a deceleration versus the last three years. Despite the slowdown, this projection is commendable and suggests the market sees success for its products and services. Software is eating the world and there is virtually no industry left that has been untouched by it. That drives increasing demand for tools helping software developers do their jobs, whether it be monitoring critical cloud infrastructure, integrating audio and video functionality, or ensuring smooth content streaming. Click here to access a free report on our 3 favorite stocks to play this generational megatrend. Customer Acquisition Efficiency The customer acquisition cost (CAC) payback period represents the months required to recover the cost of acquiring a new customer. Essentially, it's the break-even point for sales and marketing investments. A shorter CAC payback period is ideal, as it implies better returns on investment and business scalability. AppLovin is extremely efficient at acquiring new customers, and its CAC payback period checked in at 3.9 months this quarter. The company's rapid recovery of its customer acquisition costs indicates it has a highly differentiated product offering and a strong brand reputation. These dynamics give AppLovin more resources to pursue new product initiatives while maintaining the flexibility to increase its sales and marketing investments. Key Takeaways from AppLovin's Q2 Results It was encouraging to see AppLovin's revenue and EBITDA guidance for next quarter beat analysts' expectations. On the other hand, the quarter itself was weak, with revenue and EBITDA slightly falling short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 1.9% to $383.51 immediately following the results. AppLovin's latest earnings report disappointed. One quarter doesn't define a company's quality, so let's explore whether the stock is a buy at the current price. If you're making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
43 minutes ago
- Yahoo
Wells Fargo is rolling out company wide AI. It says everyone from branch tellers to investment bankers will benefit
Wells Fargo and Google Cloud are further cementing their longstanding strategic partnership with the introduction of artificially intelligent agents into Wells Fargo's systems, the companies announced today. AT&T to pay $177 million in data breach settlement. Here's how to claim up to $5,000 Wells Fargo is rolling out company wide AI. It says everyone from branch tellers to investment bankers will benefit Want to get smarter? Neuroscience says 5 simple steps significantly boost memory, learning, and cognition As part of the agreement, Wells Fargo employees—everyone from tellers to investment bankers to C-suite executives—will be able to utilize AI agents via Google Agentspace, Google Cloud's agentic AI platform. The rollout will begin immediately with 2,000 Wells Fargo employees and will continue to be expanded over the coming months. What does it mean for customers? Quicker, better service—theoretically. The AI agents are expected to help Wells Fargo's teams become faster at automating tasks, quicker at analyzing information, and overall more efficient at their jobs, the companies say. For example, Wells Fargo's banking business generates some 50,000 credit-related memos every year. A custom-built AI agent could conceivably tap into complex financial data, trends, and risk assessments to generate the first draft. 'Wells Fargo's adoption of Google Agentspace marks a bold step forward in making banking simpler and smarter—for our customers and employees,' says Tracy Kerrins, consumer CIO and head of enterprise generative AI at Wells Fargo. 'By leveraging advanced agentic AI capabilities, we can get answers and insights faster, work more efficiently, and free up time to focus on what matters most: helping people reach their financial goals.' What guardrails are in place? One thing that both Wells Fargo and Google Cloud's team are putting front and center is what they describe as a more responsible approach to AI deployment. In a statement, the two companies said their collaboration is 'underpinned by rigorous ethical and regulatory frameworks so that these powerful tools are used in a way that promotes accuracy, fairness, transparency, accountability, and security.' As companies across various industries team up with tech platforms to roll out generative AI products, some have drawn the ire of privacy and copyright advocates, among others. Financial services are seen as particularly complicated use cases for AI given the strict regulatory and compliance requirements under which banks operate, to say nothing of the need to maintain consumer trust and protect sensitive private financial data. A report from the U.S. Government Accountability Office (GAO) earlier this year found that while AI can lead to reduced costs and improved efficiency for financial institutions, 'AI also poses risks, including potentially biased lending decisions, data quality issues, privacy concerns, and new cybersecurity threats.' In the near term, it'll be interesting to see if agentic AI proves to be a difference-maker for Wells Fargo in a competitive financial services space. 'Our work with Wells Fargo is a defining moment for agentic AI in the financial services industry,' says Matt Renner, president of global revenue at Google Cloud. 'By equipping everyone from branch bankers to corporate teams with Google AI tools, Wells Fargo will unlock new levels of efficiency.' This post originally appeared at to get the Fast Company newsletter: Sign in to access your portfolio
